Profile: Hybrisens Technology, BioManager Associates, Inc. develops new versions of proven protein drugs in order to reduce adverse side effects and achieve higher clinical utilities. We offer chimeric versions of interleukins (IL-2, IL-6) targeted towards disease indications such as renal cell (kidney) carcinoma, melanoma (skin) cancer and AIDS.
4 Products/Services (Click for related suppliers)
| |||||
• | Human Interleukins (IL) | • | Interleukin Fragments | • | Interleukins |
• | Protein & Peptide-Based Drugs |